Beryl Capital Management LLC 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-10 4:52 pm Purchase | 2025-01-02 | 13G | Revance Therapeutics, Inc. RVNC | Beryl Capital Management LLC | 6,359,570 6.100% | 4,717,122 (+287.20%) | Filing |
| 2024-09-16 5:01 pm Purchase | 2024-09-05 | 13G | Revance Therapeutics, Inc. RVNC | Beryl Capital Management LLC | 1,642,448 1.600% | 1,642,448 (New Position) | Filing |